retatrutide clinical trial data Reta & dosing — a must read (Reta) isn't just another GLP-1. It's a triple-agonist peptide studied in Phase 3 trials for metabolic health — targeting GLP-1, GIP retatrutide clinical trial safety data

2026, Patil and Mitra 2026, Foster and Murray 2026, Ajmera et al

Front Vet Sci (2022) 9:1050467/FULL

However, detailed results from these trials have not been published in peer-reviewed journals, limiting comprehensive assessment of clinical efficacy

In a recent study, researchers at Southeast University and Huazhong University of Science and Technology found that GLP-1 therapy alleviates depression-like behaviors by altering the gut microbiome

A 2024 French study found that women who used the drug for at least one year were 5.6-times more likely to develop a brain tumor called an intracranial meningioma

Key Features Sensitive and accurate